{"id":49072,"date":"2023-07-19T18:54:37","date_gmt":"2023-07-19T16:54:37","guid":{"rendered":"https:\/\/newserver.fyb.de\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/"},"modified":"2023-07-19T18:55:19","modified_gmt":"2023-07-19T16:55:19","slug":"gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/","title":{"rendered":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares"},"content":{"rendered":"<p><strong>Frank\u00adfurt, London and Munich \u2014 <\/strong> Biosynth, a port\u00adfo\u00adlio company of KKR has acqui\u00adred cela\u00adres GmbH. The parties have agreed not to disc\u00adlose details of the tran\u00adsac\u00adtion. Gibson, Dunn &amp; Crut\u00adcher LLP advi\u00adsed Biosynth on this transaction.<\/p>\n<p style=\"font-weight: 400;\">cela\u00adres GmbH focu\u00adses on the deve\u00adlo\u00adp\u00adment and produc\u00adtion of poly\u00admer-based drug carri\u00aders and biocon\u00adju\u00adga\u00adted drugs. Foun\u00added in 2003, the Berlin-based company is a leader in the field of biocon\u00adju\u00adga\u00adtion and half-life exten\u00adsion by chemi\u00adcal modi\u00adfi\u00adca\u00adtion, as well as the synthe\u00adsis of specialty poly\u00admers for drug deli\u00advery. cela\u00adres offers high-quality, custo\u00admi\u00adzed services, inclu\u00adding feasi\u00adbi\u00adlity studies, up-scaling and process deve\u00adlo\u00adp\u00adment, as well as the deve\u00adlo\u00adp\u00adment and vali\u00adda\u00adtion of the requi\u00adred analy\u00adti\u00adcal methods. In addi\u00adtion, cela\u00adres offers GMP produc\u00adtion of biocon\u00adju\u00adga\u00adtes and func\u00adtion\u00ada\u00adli\u00adzed poly\u00admers used as exci\u00adpi\u00adents in drug formulation.<\/p>\n<p style=\"font-weight: 400;\">Biosynth is a criti\u00adcal mate\u00adri\u00adals supplier with global rese\u00adarch, manu\u00adfac\u00adtu\u00adring and distri\u00adbu\u00adtion faci\u00adli\u00adties secu\u00adring the supply chains of the life science indus\u00adtry. Biosynth supplies the phar\u00admaceu\u00adti\u00adcal and diagno\u00adstic sectors. Where chemis\u00adtry meets biology, products meet services and inno\u00adva\u00adtion meets quality, Biosynth is \u201cat the Edge of Inno\u00adva\u00adtion\u201d. With a unique rese\u00adarch product port\u00adfo\u00adlio of more than one million products and compre\u00adhen\u00adsive manu\u00adfac\u00adtu\u00adring services, Biosynth has exper\u00adtise and capa\u00adbi\u00adli\u00adties in complex chemi\u00adcals, pepti\u00addes and key biolo\u00adgi\u00adcal products \u2014 all from one trus\u00adted part\u00adner. Biosynth, head\u00adquar\u00adte\u00adred in Staad, Switz\u00ader\u00adland, is owned by KKR, Amper\u00adsand Capi\u00adtal Part\u00adners and manage\u00adment, among others.<\/p>\n<p style=\"font-weight: 400;\"><strong>Consul\u00adtant Biosynth: Gibson Dunn<\/strong><br>\nLed by London part\u00adner Wim De Vlie\u00adger and Frank\u00adfurt part\u00adner Dr. Jan Schu\u00adbert, the team included London coun\u00adsel Jakob Egle and asso\u00adcia\u00adtes Dr. Mattias Prange, Lena Pirner (both Frank\u00adfurt) and Romain Tourenne (London).<br>\nIn Munich, part\u00adner Kai Gesing and asso\u00adcia\u00adtes Yannick Ober\u00adacker and Chris\u00adtoph Jacob advi\u00adsed on IP issues, and part\u00adner Dr. Mark Zimmer advi\u00adsed on employ\u00adment law issues. Part\u00adner Attila Borsos (Brussels) and Asso\u00adciate Alana Tink\u00adler (London) advi\u00adsed on anti\u00adtrust issues and aspects of foreign direct investment.<\/p>\n<p style=\"font-weight: 400;\">Gibson Dunn regu\u00adlarly advi\u00adses Biosynth and&nbsp;KKR.<\/p>\n<p style=\"font-weight: 400;\"><strong>About Gibson Dunn<\/strong><\/p>\n<p style=\"font-weight: 400;\">Gibson, Dunn &amp; Crut\u00adcher LLP is one of the leading inter\u00adna\u00adtio\u00adnal law firms and is ranked among the top law firms world\u00adwide in indus\u00adtry surveys and by autho\u00adri\u00adta\u00adtive publi\u00adca\u00adti\u00adons. With more than 1,800 lawy\u00aders in 20 offices, the firm has a global presence in all major econo\u00admic regi\u00adons. Gibson Dunn offices are loca\u00adted in Abu Dhabi, Brussels, Century City, Dallas, Denver, Dubai, Frank\u00adfurt, Hong Kong, Hous\u00adton, London, Los Ange\u00adles, Munich, New York, Orange County, Palo Alto, Paris, Beijing, San Fran\u00adcisco, Singa\u00adpore and Washing\u00adton, D.C. For more infor\u00adma\u00adtion, visit <a href=\"x-webdoc:\/\/2315FBB1-67D1-4072-9E43-EA34B7B02B79\/www.gibsondunn.com\">www.gibsondunn.com<\/a>.<\/p>\n<p style=\"font-weight: 400;\">\n<\/p><p style=\"font-weight: 400;\">\n<\/p>","protected":false},"excerpt":{"rendered":"<p>Frank\u00adfurt, London and Munich \u2014 Biosynth, a port\u00adfo\u00adlio company of KKR has acqui\u00adred cela\u00adres GmbH. The parties have agreed not to disc\u00adlose details of the tran\u00adsac\u00adtion. Gibson, Dunn &amp; Crut\u00adcher LLP advi\u00adsed Biosynth on this tran\u00adsac\u00adtion. cela\u00adres GmbH focu\u00adses on the deve\u00adlo\u00adp\u00adment and produc\u00adtion of poly\u00ad\u00admer-based drug carri\u00aders and biocon\u00adju\u00adga\u00adted drugs. Foun\u00added in 2003,&nbsp;the&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":49070,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1369],"tags":[],"class_list":["post-49072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-investors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Frank\u00adfurt, London and Munich \u2014 Biosynth, a port\u00adfo\u00adlio company of KKR has acqui\u00adred cela\u00adres GmbH. The parties have agreed not to disc\u00adlose details of the tran\u00adsac\u00adtion. Gibson, Dunn &amp; Crut\u00adcher LLP advi\u00adsed Biosynth on this transaction. cela\u00adres GmbH focu\u00adses on the deve\u00adlo\u00adp\u00adment and produc\u00adtion of poly\u00admer-based drug carri\u00aders and biocon\u00adju\u00adga\u00adted drugs. Foun\u00added in 2003, the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-19T16:54:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-19T16:55:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"469\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares\",\"datePublished\":\"2023-07-19T16:54:37+00:00\",\"dateModified\":\"2023-07-19T16:55:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg\",\"articleSection\":[\"General\",\"Featured\",\"Private equity\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Investors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\",\"url\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\",\"name\":\"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg\",\"datePublished\":\"2023-07-19T16:54:37+00:00\",\"dateModified\":\"2023-07-19T16:55:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg\",\"width\":469,\"height\":458},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/","og_locale":"en_US","og_type":"article","og_title":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook","og_description":"Frank\u00adfurt, London and Munich \u2014 Biosynth, a port\u00adfo\u00adlio company of KKR has acqui\u00adred cela\u00adres GmbH. The parties have agreed not to disc\u00adlose details of the tran\u00adsac\u00adtion. Gibson, Dunn &amp; Crut\u00adcher LLP advi\u00adsed Biosynth on this transaction. cela\u00adres GmbH focu\u00adses on the deve\u00adlo\u00adp\u00adment and produc\u00adtion of poly\u00admer-based drug carri\u00aders and biocon\u00adju\u00adga\u00adted drugs. Foun\u00added in 2003, the [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2023-07-19T16:54:37+00:00","article_modified_time":"2023-07-19T16:55:19+00:00","og_image":[{"width":469,"height":458,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares","datePublished":"2023-07-19T16:54:37+00:00","dateModified":"2023-07-19T16:55:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/"},"wordCount":412,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg","articleSection":["General","Featured","Private equity","News","Lawyers\/Tax-advisors\/Auditors","Investors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/","url":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/","name":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg","datePublished":"2023-07-19T16:54:37+00:00","dateModified":"2023-07-19T16:55:19+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/07\/dr-jan-schubert.jpg","width":469,"height":458},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-subsidiary-biosynth-on-acquisition-of-celares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Gibson Dunn advises KKR subsidiary Biosynth on acquisition of celares"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/49072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=49072"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/49072\/revisions"}],"predecessor-version":[{"id":49073,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/49072\/revisions\/49073"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/49070"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=49072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=49072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=49072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}